- Home
- LDWY vs ACXP Comparison
LDWY vs ACXP Comparison
Compare LDWY & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- ACXP
- Stock Information
- Founded
- LDWY 1990
- ACXP 2017
- Country
- LDWY United States
- ACXP United States
- Employees
- LDWY N/A
- ACXP N/A
- Industry
- LDWY Advertising
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- ACXP Health Care
- Exchange
- LDWY Nasdaq
- ACXP Nasdaq
- Market Cap
- LDWY 9.2M
- ACXP 9.1M
- IPO Year
- LDWY 1991
- ACXP 2021
- Fundamental
- Price
- LDWY $5.51
- ACXP $4.45
- Analyst Decision
- LDWY
- ACXP Strong Buy
- Analyst Count
- LDWY 0
- ACXP 3
- Target Price
- LDWY N/A
- ACXP $143.67
- AVG Volume (30 Days)
- LDWY 4.2K
- ACXP 88.7K
- Earning Date
- LDWY 08-28-2025
- ACXP 08-12-2025
- Dividend Yield
- LDWY N/A
- ACXP N/A
- EPS Growth
- LDWY N/A
- ACXP N/A
- EPS
- LDWY N/A
- ACXP N/A
- Revenue
- LDWY $42,183,000.00
- ACXP N/A
- Revenue This Year
- LDWY N/A
- ACXP N/A
- Revenue Next Year
- LDWY N/A
- ACXP N/A
- P/E Ratio
- LDWY N/A
- ACXP N/A
- Revenue Growth
- LDWY 425.12
- ACXP N/A
- 52 Week Low
- LDWY $3.02
- ACXP $3.80
- 52 Week High
- LDWY $6.19
- ACXP $44.90
- Technical
- Relative Strength Index (RSI)
- LDWY 60.48
- ACXP 38.08
- Support Level
- LDWY $5.39
- ACXP $4.40
- Resistance Level
- LDWY $5.20
- ACXP $7.15
- Average True Range (ATR)
- LDWY 0.22
- ACXP 0.61
- MACD
- LDWY 0.04
- ACXP 0.15
- Stochastic Oscillator
- LDWY 52.45
- ACXP 30.15
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.